Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients
A Phase IIa, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Seraprevir in Combination With Sofosbuvir in Patients With Chronic Genotype 2,3,6 Hepatitis C Virus Infection
Sponsor: Ginkgopharma CO., LTD
Listed as NCT04111367, this PHASE2 trial focuses on Hepatitis C Virus Infection and remains ongoing. Sponsored by Ginkgopharma CO., LTD, it has been updated 6 times since 2019, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
6 versions recorded-
Dec 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Dec 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Oct 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Nov 2019 — Jan 2021 [monthly]
Recruiting PHASE2
First recorded
Apr 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ginkgopharma CO., LTD
For direct contact, visit the study record on ClinicalTrials.gov .